Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
15 pending office actions • 12 art units • 15 examiners • 0 of 15 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Biontech SE manages a patent portfolio with 14 pending office actions in the Biotechnology & Pharmaceuticals technology area. The prosecution is distributed across 11 distinct art units, indicating a range of technical subject matter. This breadth is further reflected in the involvement of 14 distinct examiners, meaning every pending action is currently assigned to a different individual. DEEPA MISHRA is identified as the busiest examiner, responsible for 1 pending office action.
The high number of 14 distinct examiners across 11 distinct art units suggests a complex prosecution landscape that requires managing numerous unique examiner interactions. Practitioners must coordinate strategies across the pending office actions to ensure consistency in the Biotechnology & Pharmaceuticals space. With 11 distinct art units involved, the technical expertise required to manage the portfolio is significant. The fact that DEEPA MISHRA and the other examiners each handle a pending office action means the company must track multiple separate prosecution timelines. This level of activity across the pending office actions demonstrates the extensive commitment to securing intellectual property across a wide array of art units. The 1 pending office action under DEEPA MISHRA is just a part of the total workload.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (20%) |
| §112 only | 1 (7%) |
| Double-patenting + other | 3 (20%) |
| Multi-statute (no §101) | 7 (47%) |
| No statute on record | 1 (7%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MISHRA, DEEPA | 1 | 29.3% | +35.2% |
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.1% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
| ISKRA, JOSEPH W | 1 | 71.3% | +27.2% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
| ZAHORIK, AMANDA MARY | 1 | 57.8% | +49.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17915567 | RNA COMPOSITIONS TARGETING CLAUDIN-18.2 | LI, RUIXIANG | 67d overdue |
| 18268124 | THERAPEUTIC RNA FOR TREATING CANCER | LIPPOLIS, ALEXANDRA ROSE | 4d overdue |
| 18044955 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | VAN BUREN, LAUREN K | 29d |
| 17920569 | CORONAVIRUS VACCINE | SPICER, JENINE MARIE | 55d |
| 18837311 | NOVEL THERAPEUTIC USES OF GARDNERELLA ENDOLYSINS | MISHRA, DEEPA | — |
| 18696689 | MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY | GUSTILO, ESTELLA M | — |
| 18563738 | DEVICE AND METHOD FOR ACCELERATED THAWING | ISKRA, JOSEPH W | — |
| 18266135 | RNA MANUFACTURING | ZAHORIK, AMANDA MARY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268124 | THERAPEUTIC RNA FOR TREATING CANCER | LIPPOLIS, ALEXANDRA ROSE | 4d overdue |
| 18258343 | Therapeutic RNA for Treating Cancer | PUTTLITZ, KARL J | 26d |
| 18837311 | NOVEL THERAPEUTIC USES OF GARDNERELLA ENDOLYSINS | MISHRA, DEEPA | — |
| 18724236 | LIPID-BASED FORMULATIONS FOR ADMINISTRATION OF RNA | PERSONS, JENNA L | — |
| 18708333 | RNA ENCODING PEPTIDOGLYCAN HYDROLASE AND USE THEREOF FOR TREATING BACTERIAL INFECTION | ROBINSON, HOPE A | — |
| 18696689 | MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY | GUSTILO, ESTELLA M | — |
| 18570257 | COMBINATION DOSAGE REGIME OF CD137 AND PD-L1 BINDING AGENTS | METCALF, MATTHEW CURRAN | — |
| 18563738 | DEVICE AND METHOD FOR ACCELERATED THAWING | ISKRA, JOSEPH W | — |
| Art Unit | Apps |
|---|---|
| 1646 | 2 |
| 1699 | 1 |
| 1652 | 1 |
| 3781 | 1 |
| 1642 | 1 |
| 1637 | 1 |
| 1636 | 1 |
| 1641 | 1 |
| 1638 | 1 |
| 3736 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837311 | NOVEL THERAPEUTIC USES OF GARDNERELLA ENDOLYSINS | MISHRA, DEEPA | — | §102§112DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18724236 | LIPID-BASED FORMULATIONS FOR ADMINISTRATION OF RNA | PERSONS, JENNA L | 1699 | §103§112DP | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18708333 | RNA ENCODING PEPTIDOGLYCAN HYDROLASE AND USE THEREOF FOR TREATING BACTERIAL INFECTION | ROBINSON, HOPE A | 1652 | §112 | Final Rejection | — | Pending | May 08, 2024 |
| 18696689 | MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY | GUSTILO, ESTELLA M | 1646 | §102§103§112Other | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18570257 | COMBINATION DOSAGE REGIME OF CD137 AND PD-L1 BINDING AGENTS | METCALF, MATTHEW CURRAN | — | §103§112DP | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18563738 | DEVICE AND METHOD FOR ACCELERATED THAWING | ISKRA, JOSEPH W | 3781 | §103§112 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18549346 | MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN THERAPY | AEDER, SEAN E | 1642 | §103Other | Non-Final OA | — | Pending | Sep 06, 2023 |
| 18258343 | Therapeutic RNA for Treating Cancer | PUTTLITZ, KARL J | 1646 | — | Final Rejection | 26d | Pending | Jun 20, 2023 |
| 18268124 | THERAPEUTIC RNA FOR TREATING CANCER | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103§112 | Final Rejection | 4d overdue | Pending | Jun 16, 2023 |
| 18266135 | RNA MANUFACTURING | ZAHORIK, AMANDA MARY | 1636 | §103§112Other | Final Rejection | — | Pending | Jun 08, 2023 |
| 18134844 | NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A | HADDAD, MAHER M | 1641 | §103Other | Final Rejection | 70d | Pending | Apr 14, 2023 |
| 18044955 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | VAN BUREN, LAUREN K | 1638 | §103§112 | Final Rejection | 29d | Pending | Mar 10, 2023 |
| 17920569 | CORONAVIRUS VACCINE | SPICER, JENINE MARIE | 3736 | §103§112 | Final Rejection | 55d | Pending | Oct 21, 2022 |
| 17915567 | RNA COMPOSITIONS TARGETING CLAUDIN-18.2 | LI, RUIXIANG | 1674 | §103§112 | Final Rejection | 67d overdue | Pending | Sep 29, 2022 |
| 17609358 | NOVEL GARDNERELLA ENDOLYSINS AND USES THEREOF | EDWARDS, JESSICA FAYE | 1657 | §103 | Final Rejection | — | Pending | Nov 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial